CLINICAL TRIALS PROFILE FOR TAK-906
✉ Email this page to a colleague
Clinical Trials for TAK-906
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03161405 ↗ | A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate. |
| NCT03237156 ↗ | Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants | Completed | Takeda | Phase 1 | The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male participants. |
| NCT03268941 ↗ | A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG) | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for TAK-906
Condition Name
Clinical Trial Locations for TAK-906
Trials by Country
Clinical Trial Progress for TAK-906
Clinical Trial Phase
Clinical Trial Sponsors for TAK-906
Sponsor Name
